Evidence map›Paper›PMID 29955655›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2018

Virtual reality-based cognitive-motor training for middle-aged adults at high Alzheimer's disease risk: A randomized controlled trial.

Glen M Doniger, Michal Schnaider Beeri, Alex Bahar-Fuchs, Amihai Gottlieb, Anastasia Tkachov, Hagar Kenan, Abigail Livny, Yotam Bahat, Hadar Sharon, Oran Ben-Gal and 3 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06072963 (Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow), which is not on this map. Cited by 40 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 6 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruitingstarted 2024, after this paper: background citation

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Review
  13. Emotional response to amyloid beta status disclosure among research participants at high dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Glen M DonigerCenter of Advanced Technologies in Rehabilitation, Sheba Medical Center, Ramat Gan, Israel.
Michal Schnaider BeeriJoseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel.
Alex Bahar-FuchsJoseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel.
Amihai GottliebCenter of Advanced Technologies in Rehabilitation, Sheba Medical Center, Ramat Gan, Israel.
Anastasia TkachovJoseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel.
Hagar KenanJoseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel.
Abigail LivnyJoseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel.
Yotam BahatCenter of Advanced Technologies in Rehabilitation, Sheba Medical Center, Ramat Gan, Israel.
Hadar SharonCenter of Advanced Technologies in Rehabilitation, Sheba Medical Center, Ramat Gan, Israel.
Oran Ben-GalCenter of Advanced Technologies in Rehabilitation, Sheba Medical Center, Ramat Gan, Israel.
Maya CohenCenter of Advanced Technologies in Rehabilitation, Sheba Medical Center, Ramat Gan, Israel.
Gabi ZeiligSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Meir PlotnikCenter of Advanced Technologies in Rehabilitation, Sheba Medical Center, Ramat Gan, Israel.
Sheba Medical Center · ILAustralian National University · AUReichman University · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionUbiquity of Alzheimer's disease (AD) coupled with relatively ineffectual pharmacologic treatments has spurred interest in nonpharmacologic lifestyle interventions for prevention or risk reduction. However, evidence of neuroplasticity notwithstanding, there are few scientifically rigorous, ecologically relevant brain training studies focused on building cognitive reserve in middle age to protect against cognitive decline. This pilot study will examine the ability of virtual reality (VR) cognitive training to improve cognition and cerebral blood flow (CBF) in middle-aged individuals at high AD risk due to parental history.

methodsThe design is an assessor-blind, parallel group, randomized controlled trial of VR cognitive-motor training in middle-aged adults with AD family history. The experimental group will be trained with adaptive "real-world" VR tasks targeting sustained and selective attention, working memory, covert rule deduction, and planning, while walking on a treadmill. One active control group will perform the VR tasks without treadmill walking; another will walk on a treadmill while watching scientific documentaries (nonspecific cognitive stimulation). A passive (waitlist) control group will not receive training. Training sessions will be 45 minutes, twice/week for 12 weeks. Primary outcomes are global cognition and CBF (from arterial spin labeling [ASL]) at baseline, immediately after training (training gain), and 3 months post-training (maintenance gain). We aim to recruit 125 participants, including 20 passive controls and 35 in the other groups. DISCUSSION: Current pharmacologic therapies are for symptomatic AD patients, whereas nonpharmacologic training is administrable before symptom onset. Emerging evidence suggests that cognitive training improves cognitive function. However, a more ecologically valid cognitive-motor VR setting that better mimics complex daily activities may augment transfer of trained skills. VR training has benefited clinical cohorts, but benefit in asymptomatic high-risk individuals is unknown. If effective, this trial may help define a prophylactic regimen for AD, adaptable for home-based application in high-risk individuals.

Indexed as

Alzheimer's diseaseArterial spin labelingCerebral blood flowCognitionCognitive trainingMRINeuroplasticityPreventionVirtual reality

Identifiers

PMID29955655
PMCPMC6021455
OpenAlexW2794532029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.